Imaging of bioluminescent LNCaP-luc-M6 Tumors: A new animal model for the study of metastatic human prostate cancer
Article first published online: 3 FEB 2004
Copyright © 2004 Wiley-Liss, Inc.
Volume 59, Issue 3, pages 292–303, 15 May 2004
How to Cite
Scatena, C. D., Hepner, M. A., Oei, Y. A., Dusich, J. M., Yu, S.-F., Purchio, T., Contag, P. R. and Jenkins, D. E. (2004), Imaging of bioluminescent LNCaP-luc-M6 Tumors: A new animal model for the study of metastatic human prostate cancer. Prostate, 59: 292–303. doi: 10.1002/pros.20003
- Issue published online: 19 MAR 2004
- Article first published online: 3 FEB 2004
- Manuscript Accepted: 6 OCT 2003
- Manuscript Received: 29 APR 2003
- orthotopic prostate model;
- biophotonic imaging (BLI);
- firefly luciferase;
- mouse xenograft model;
Animal experiments examining hormone-sensitive metastatic prostate cancer using the human LNCaP cell line have been limited to endpoint analyses. To permit longitudinal studies, we generated a luciferase-expressing cell line and used bioluminescent imaging (BLI) to non-invasively monitor the in vivo growth of primary LNCaP tumors and metastasis.
LNCaP.FGC cells were transfected to constitutively express firefly luciferase. LNCaP-luc-M6 cells were tested for bioluminescent signal intensity and hormone responsiveness in vitro. The cells were implanted in subcutaneous and orthotopic sites in SCID-bg mice and imaged over time.
The LNCaP-luc-M6 cells formed subcutaneous and orthotopic tumors in SCID-bg mice, and nearly all tumor-bearing animals developed pulmonary metastases. Early detection and temporal growth of primary tumors and metastatic lesions was successfully monitored by BLI.
The LNCaP-luc-M6 cell line is a bioluminescent, hormone-sensitive prostate cancer cell line applicable for BLI studies to non-invasively monitor subcutaneous and orthotopic prostate tumor growth and metastasis in vivo. © 2004 Wiley-Liss, Inc.